Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SCYX

Scynexis Inc

Feb 17 • 10:01AM ET

0.7700

+0.0200 2.67 %

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Peers: GSK PFE MRK BMY JNJ LLY GILD REGN VRTX ABBV

| Held by: VTI VXF BSVO

Index	-	P/E	-	EPS (ttm)	-0.54	Insider Own	6.31%	Shs Outstand	41.96M	Perf Week	2.60%
Market Cap	32.31M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	0.00%	Shs Float	39.32M	Perf Month	19.92%
Enterprise Value	-3.42M	PEG	-	EPS next Q	0.13	Inst Own	35.63%	Short Float	2.86%	Perf Quarter	30.49%
Income	-25.30M	P/S	11.03	EPS this Y	28.79%	Inst Trans	11.82%	Short Ratio	2.32	Perf Half Y	-8.32%
Sales	2.93M	P/B	0.89	EPS next Y	81.91%	ROA	-33.71%	Short Interest	1.13M	Perf YTD	21.76%
Book/sh	0.87	P/C	0.85	EPS next 5Y	0.25%	ROE	-53.29%	52W High	1.31 -41.22%	Perf Year	-31.25%
Cash/sh	0.91	P/FCF	-	EPS past 3/5Y	29.37% 46.02%	ROIC	-66.14%	52W Low	0.56 36.28%	Perf 3Y	-49.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-34.22% 98.68%	Gross Margin	-	Volatility	7.93% 8.67%	Perf 5Y	-91.76%
Dividend TTM	-	EV/Sales	-1.17	EPS Y/Y TTM	38.61%	Oper. Margin	-1181.07%	ATR (14)	0.05	Perf 10Y	-98.44%
Dividend Ex-Date	-	Quick Ratio	5.75	Sales Y/Y TTM	-65.77%	Profit Margin	-862.89%	RSI (14)	55.61	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.75	EPS Q/Q	-197.92%	SMA20	2.39%	Beta	1.32	Target Price	3.67
Payout	-	Debt/Eq	0.06	Sales Q/Q	-49.39%	SMA50	12.71%	Rel Volume	0.13	Prev Close	0.75
Employees	28	LT Debt/Eq	0.05	Earnings	Nov 05 AMC	SMA200	-0.54%	Avg Volume	484.48K	Price	0.77
IPO	May 02, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.00% 150.56%	Trades		Volume	8,931	Change	2.67%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-21	Initiated	Guggenheim	Buy	$25
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight	$30
Jul-11-18	Upgrade	Needham	Hold → Buy	$5
Jun-27-18	Initiated	Maxim Group	Buy	$6
Oct-24-17	Initiated	Guggenheim	Buy	$6
Jul-10-17	Initiated	ROTH Capital	Buy	$8.50
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform	$15 → $11
Oct-20-16	Initiated	H.C. Wainwright	Buy	$14
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy	$8
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy	$15
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy	$8
Aug-09-16	Reiterated	Needham	Buy	$16 → $10
Mar-28-16	Initiated	Brean Capital	Buy	$16
Dec-29-15	Initiated	WBB Securities	Strong Buy	$8
Dec-29-15	Initiated	WBB Securities	Speculative Buy	$8
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform	$18 → $17
Jun-10-15	Initiated	Needham	Buy	$16
May-29-14	Initiated	RBC Capital Mkts	Outperform	$17

Show Previous Ratings

Jan-28-26 08:00AM	SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) (GlobeNewswire)
Jan-21-26 08:00AM	SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247 (GlobeNewswire)
Dec-22-25 08:00AM	SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (GlobeNewswire)
Nov-19-25 07:00AM	SCYNEXIS Completes Transfer of BREXAFEMME New Drug Application to GSK (GlobeNewswire)
Nov-17-25 10:15AM	Scynexis Announces Federal Funding of Collaboration Between Hackensack Meridian CDI and Johns Hopkins Researchers to Develop New Therapeutics, Including Novel Fungerps, for Resistant Fungal Infections (GlobeNewswire)
04:51PM	Loading…
Nov-05-25 04:51PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance) -5.48%
04:20PM	SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-25 08:07AM	SCYNEXIS Reports Positive Phase 1 Results for Second-Generation Antifungal SCY-247 (Insider Monkey)
Oct-15-25 08:00AM	SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study (GlobeNewswire)
Oct-01-25 07:10AM	SCYNEXIS announces favourable Phase I data for SCY-247 trial (Clinical Trials Arena)
Sep-30-25 08:00AM	SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247) (GlobeNewswire) -26.67%
Sep-04-25 08:30AM	SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) (GlobeNewswire)
Aug-25-25 08:00AM	SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 - 10, 2025 (GlobeNewswire)
Aug-13-25 04:35PM	Scynexis: Q2 Earnings Snapshot (Associated Press Finance) -5.15%
04:30PM	SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
12:31AM	Loading…
May-29-25 12:31AM	SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold (Insider Monkey)
May-28-25 12:23PM	Scynexis resumes dosing in Phase III MARIO study after lengthy delay (Clinical Trials Arena) +28.04%
08:30AM	SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study (GlobeNewswire)
May-15-25 04:56PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance) -19.29%
04:20PM	SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-08-25 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) (GlobeNewswire)
Mar-12-25 05:08PM	SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -5.90%
Dec-18-24 08:00AM	SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections (GlobeNewswire) -9.01%
Nov-06-24 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-10-24 08:00AM	SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-07-24 05:02PM	Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc (GuruFocus.com)
Oct-03-24 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 (GlobeNewswire)
Aug-27-24 08:00AM	SCYNEXIS to Participate in H. C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.73%
Aug-08-24 05:44PM	Scynexis: Q2 Earnings Snapshot (Associated Press Finance) -7.85%
04:30PM	Loading…
04:30PM	SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-23-24 07:00AM	SCYNEXIS to Receive $10 Million Milestone Payment from GSK Triggered by Delivery of Completed FURI, CARES and NATURE Clinical Study Reports (GlobeNewswire)
Jul-22-24 06:24AM	3 Stocks Under $10 With the Potential for Massive Gains (InvestorPlace)
Jul-11-24 07:00AM	3 Dirt-Cheap Drug Developers With Blockbuster Potential (InvestorPlace) +12.69%
Jul-01-24 02:18PM	7 Undervalued Biotech Stocks to Buy for Big-Time Returns (InvestorPlace)
May-31-24 11:50AM	Hidden Gems: 3 Under-$10 Stocks Poised for 500% Growth by 2025 (InvestorPlace)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace) -11.46%
May-08-24 11:54PM	SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:51PM	Scynexis: Q1 Earnings Snapshot (Associated Press Finance)
04:30PM	SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-30-24 04:05PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) (GlobeNewswire) -7.14%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Apr-09-24 04:05PM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) (GlobeNewswire)
Mar-28-24 11:53PM	SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-30-24 04:05PM	SCYNEXIS to Participate in Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire) +5.37%
Jan-29-24 05:15PM	SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference (GlobeNewswire)
Jan-05-24 08:30AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 27, in Milan, Italy (GlobeNewswire)
Dec-27-23 09:30AM	SCYNEXIS SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Nov-27-23 10:33AM	11 Cheapest Stocks With Biggest Upside (Insider Monkey)
Nov-15-23 01:15PM	SCYX STOCKHOLDERS: Contact Robbins LLP for Information About Your Rights Against Scynexis, Inc. (Business Wire)
Nov-13-23 05:55PM	Scynexis: Q3 Earnings Snapshot (Associated Press Finance)
05:17PM	SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-24-23 08:00AM	SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-16-23 08:00AM	SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece (GlobeNewswire) +6.12%
Oct-02-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Orthofix, and Scynexis and Encourages Investors to Contact the Firm (GlobeNewswire)
Sep-27-23 08:31PM	SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance (GlobeNewswire) +9.33% +9.00%
07:49AM	Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock? (Zacks)
Sep-25-23 08:55AM	UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk (Reuters) -34.14%
Sep-20-23 04:00AM	PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains? (Zacks) +5.01%
Sep-04-23 01:31PM	SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why (Zacks)
Aug-28-23 10:17PM	Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now (InvestorPlace) +11.96%
08:00AM	SCYNEXIS to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-23 04:59PM	Scynexis: Q2 Earnings Snapshot (AP Finance) -6.35%
04:30PM	SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-23 09:09AM	10 Best Fast Growing Penny Stocks to Buy Now (Insider Monkey)
Jul-20-23 09:58AM	SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China (GlobeNewswire) +5.69%
Jun-26-23 02:20PM	Deadly Fungi Are Becoming More Common and Were Running Out of Ways to Treat Them (The Wall Street Journal)
07:00AM	Doctors Desperately Need Drugs to Kill Deadly Fungi. Its an Uphill Fight. (The Wall Street Journal)
Jun-21-23 07:00AM	SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK (GlobeNewswire)
Jun-15-23 04:10PM	SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference (GlobeNewswire)
May-19-23 09:22AM	WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens (Newsfile)
May-12-23 08:00AM	SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets) (GlobeNewswire)
May-11-23 08:45AM	Scynexis (SCYX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:37AM	Scynexis: Q1 Earnings Snapshot (AP Finance)
07:00AM	SCYNEXIS Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 03:38PM	SCYNEXIS, Inc.'s (NASDAQ:SCYX) largest shareholders are individual investors with 51% ownership, institutions own 48% (Simply Wall St.)
Apr-13-23 08:30AM	SCYNEXIS to Present Ibrexafungerp Data at the 33rd Annual European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) April 15-18 in Denmark (GlobeNewswire)
Apr-11-23 01:33PM	We Might See A Profit From SCYNEXIS, Inc. (NASDAQ:SCYX) Soon (Simply Wall St.)
Mar-31-23 12:31PM	Scynexis (SCYX) Inks Antifungal Drug Deal With GSK (Zacks)
08:30AM	SCYNEXIS Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 01:12PM	GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks (Benzinga) +76.05%
09:36AM	Anti-Fungal Maker Scynexis Stock Soars on GSK Deal (Barrons.com)
07:05AM	GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection (GlobeNewswire)
Mar-22-23 09:25AM	CDC Rings Alarm About Deadly Fungus. 6 Things to Know. (Barrons.com) +28.21%
07:06AM	SCYNEXIS, Inc. (NASDAQ:SCYX) insiders are still down US$113k after purchasing last year, recent gain helped regain some losses (Simply Wall St.)
Mar-01-23 04:03PM	Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock (Benzinga) +16.11%
Jan-14-23 07:43AM	SCYNEXIS (NASDAQ:SCYX) shareholders are up 14% this past week, but still in the red over the last five years (Simply Wall St.)
Dec-01-22 08:00AM	SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis (GlobeNewswire) -10.17%
Nov-30-22 08:30AM	SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi (GlobeNewswire)
Nov-17-22 08:30AM	SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats (GlobeNewswire)
Nov-11-22 05:37AM	SCYNEXIS Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 08:15AM	Scynexis (SCYX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.64%
07:00AM	SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-22 08:30AM	SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi (GlobeNewswire)
Nov-03-22 08:30AM	Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Womens Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection (GlobeNewswire)
Nov-02-22 10:01AM	Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline (Zacks)
Nov-01-22 08:30AM	SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9 (GlobeNewswire)
Oct-25-22 08:30AM	Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer (GlobeNewswire) +5.41%

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

TBF ProShares Short 20+ Year Treasury -1x Shares daily Stock Chart

Category	Bonds - Leveraged / Inverse	Asset Type	Bonds	Tags	U.S.	Return% 1Y	-1.74%	Total Holdings	9	Perf Week	-2.74%
Sponsor	ProShares	ETF Type		Tags	treasuries	Return% 3Y	7.51%	AUM	68.59M	Perf Month	-1.72%
Fund Family		Bond Type		Tags	bonds	Return% 5Y	9.96%	NAV/sh		Perf Quarter	-1.22%
Index	ICE U.S. Treasury 20+ Year Bond Index	Average Maturity		Tags	inverse	Return% 10Y		52W High	25.73 -8.98%	Perf Half Y	-5.14%
Index Weighting		Commodity Type		Tags	-	Return% SI		52W Low	22.72 3.08%	Perf YTD	-2.90%
Active/Passive		Quant Type		Tags	-	Flows% 1M	6.87%	Volatility	0.57% 0.56%	Perf Year	-3.26%
Dividend TTM	0.82 (3.48%)	ESG Type		Tags	-	Flows% 3M	8.48%	ATR (14)	0.16	Perf 3Y	5.73%
Dividend Ex-Date	Dec 24, 2025	Dividend Type		Sector/Theme		Flows% YTD	6.44%	RSI (14)	33.44	Perf 5Y	38.01%
Dividend Gr. 3/5Y	115.09% 87.73%	Structure Type		Region		Flows% 1Y		Beta	-0.56	Perf 10Y	2.09%
Expense	0.95%	Growth/Value		SMA20	-2.42%	Flows% 3Y		Rel Volume	0.74	Prev Close	23.47
Inverse/Leveraged		Market Cap		SMA50	-2.55%	Flows% 5Y		Avg Volume	81.23K	Price	23.42
IPO	Aug 20, 2009	Option/Short	Yes / Yes	SMA200	-3.19%	Trades		Volume	9,447	Change	-0.21%

May-19-25 11:45AM	ETFs to Make the Most of the Long-Term Yield Surge to 5% (Zacks)
May-08-25 01:20AM	The Fed Is In A 'Good Place' - But For How Long? (Seeking Alpha)
01:05AM	Fed's Interest Rate Decision: May 7, 2025 (Seeking Alpha)
May-07-25 03:53PM	Fed's Wait And See Stance Could Persist Through To September (Seeking Alpha)
03:45PM	Fed Watch: Still Waiting (Seeking Alpha)
02:50PM	Loading…
02:50PM	Making Sense Of The Recent Contraction In Real GDP (Seeking Alpha)
02:35PM	Inflation Expectations Vs. 10-Year Treasury Yield - The (2nd) Great Conundrum (Seeking Alpha)
11:30AM	Where Are The Endpoints Of QT? Ample Reserve System Vs. Demand-Driven Floor System (Seeking Alpha)
07:30AM	Jerome Powell Should Not Bend To Trump's Pressure (Seeking Alpha)
04:30AM	Rates Spark: Stability From The Fed As A Counter To Volatility Risks (Seeking Alpha)
May-05-25 11:45AM	Fed Set To Keep Rates Steady, Despite Pressure From Trump (Seeking Alpha)
11:21AM	Fixed-Income Annual Returns And Falling Crude Oil Prices (Seeking Alpha)
08:30AM	Bullish And Bearish Records Are Plentiful. How To Anticipate What Happens Next (Seeking Alpha)
07:04AM	The End Of American Exceptionalism? (Seeking Alpha)
04:26AM	Weekly Market Pulse: Deja Vu All Over Again (Seeking Alpha)
10:10AM	Loading…
May-04-25 10:10AM	The Greed And Fear Tango: The Markets In April 2025 (Seeking Alpha)
May-03-25 12:35AM	25 Years Of Higher Interest Rates Ahead? (Seeking Alpha)
12:30AM	Markets Weekly Outlook - Central Banks In Focus As Risk Appetite Improves (Seeking Alpha)
May-02-25 11:10AM	Will Economic Contraction In The First Quarter Speed Up The Timeline For Fed Rate Cuts? (Seeking Alpha)
03:40AM	Priced For Perfection (Seeking Alpha)
03:31AM	Rates Spark: U.S. Treasuries Primed To React (Seeking Alpha)
03:05AM	May 2025 Perspective (Seeking Alpha)
May-01-25 07:35AM	U.S. Economy Stumbles Into Negative Territory Amid Rising Inflation And Imports (Seeking Alpha)
Apr-30-25 01:57PM	Rocks And Hard Places Leave No Easy Out (Seeking Alpha)
12:45PM	Very Good Report On Income, Spending, And Inflation (Seeking Alpha)
10:40AM	GDP Declines - Real Or A Head Fake? (Seeking Alpha)
10:30AM	U.S. Economy Shrinks On Import Surge (Seeking Alpha)
08:27AM	Tariff And Tumble: April's Market Mood Swings (Seeking Alpha)
03:35AM	Rates Spark: Data Doesn't Change An Uncertain Backdrop (Seeking Alpha)
Apr-29-25 04:35AM	Rates Spark: Kicking Off A Data-Driven Week (Seeking Alpha)
02:05PM	Loading…
Apr-28-25 02:05PM	Another Bessent Bounce! What Will It Take To Make #3 A Bottom? (Seeking Alpha)
09:11AM	Weekly Market Pulse: A Generational Change? (Seeking Alpha)
08:15AM	Risk-Off Following Familiar Pattern (Seeking Alpha)
Apr-26-25 03:45AM	When Debts Come Due (Seeking Alpha)
02:20AM	13-Week Money Supply Growth Continues To Decelerate (Seeking Alpha)
Apr-25-25 04:20AM	Rates Spark: Not Much Is Needed For More Dovish ECB Pricing (Seeking Alpha)
03:40AM	Challenges To Fed Independence (Seeking Alpha)
02:45AM	Above The Noise: Policy Uncertainty Persists (Seeking Alpha)
Apr-24-25 12:10PM	Fed Expected To Keep Rates Steady Despite Trump's Calls For Cuts (Seeking Alpha)
08:52AM	Looking Ahead To Q2 2025: Selective Strength In A Policy-Driven Market (Seeking Alpha)
05:30AM	Rates Spark: Dutch Pension Funds Bracing For Potential Delays (Seeking Alpha)
03:05AM	Navigating Market Volatility And Tariff Policy: Positioning Portfolios Amid Uncertainty (Seeking Alpha)
Apr-23-25 11:36AM	3 Things - China Tariffs Update (Seeking Alpha)
05:45AM	Rewiring Global Trade For Resilience And Growth (Seeking Alpha)
04:30AM	Rates Spark: Eurozone To U.S. Gap To Keep On Widening (Seeking Alpha)
Apr-21-25 11:02AM	Markets Face Another Week Of Extreme Policy Uncertainty (Seeking Alpha)
10:45AM	Why 2025 Has Been So Painful (Seeking Alpha)
09:15AM	Weekly Market Pulse: Peak America? (Seeking Alpha)
07:44AM	The 1-Minute Market Report April 20, 2025 (Seeking Alpha)
Apr-20-25 11:45PM	3 Things - Fed Independence, Bonds, Tariffs Endgame (Seeking Alpha)
Apr-18-25 03:30PM	How Effectively Can The U.S. Economy Untether From China? (Seeking Alpha)
09:47AM	Inflation Risk Is Subsiding Rapidly (Seeking Alpha)
Apr-16-25 10:20AM	The Role Different Bond Classes Can Play During Market Uncertainty (Seeking Alpha)
05:00AM	Fixed Income Investment Outlook Q2 2025 (Seeking Alpha)
04:05AM	Rates Spark: The Dust Settles, Angst Remains (Seeking Alpha)
03:35AM	Do Indicators Point To Potential Further Stock Market Declines? (Seeking Alpha)
02:40AM	Treasuries, Sentiment, And Earnings: What Investors Need To Watch (Seeking Alpha)
Apr-15-25 01:19PM	The Bond Market Is Controlling Trump Now: Why Rising Rates Are A Good Thing (Seeking Alpha)
11:20AM	Global Leading Indicators, March 2025 - The World Before Tariffs, And After (Seeking Alpha)
11:10AM	What The U.S. Bond Market Is Telling Us About Investor Sentiment And The Economy (Seeking Alpha)
09:20AM	Rates: U.S. Treasuries Have Become A 'Pain Trade' (Seeking Alpha)
06:10AM	U.S. Trade Policy: PIMCO's Libby Cantrill Addresses Client Questions (Seeking Alpha)
04:30AM	Rates Spark: Equity Optimism Not Shared By Rates (Seeking Alpha)
Apr-14-25 03:05PM	The Money Supply Keeps Growing As The Fed Backs Off Monetary 'Tightening' (Seeking Alpha)
02:55PM	The Fog Of Tariffs (Seeking Alpha)
12:20PM	April 2025 Commentary And Economic Outlook (Seeking Alpha)
11:05AM	10-Year Treasury Yield Snaps Back To February's 4.5%, Yield Curve Re-Un-Inverts, Mortgage Rates Back At 7% (Seeking Alpha)
10:49AM	Is The Market Pricing In A Higher Risk Premium For U.S. Treasuries? (Seeking Alpha)
10:15AM	Rough Ride Exacting A Toll (Seeking Alpha)
09:10AM	Yield Spreads Suggest The Risk Isn't Over Yet (Seeking Alpha)
07:50AM	Weekly Market Pulse: The End Of The Beginning (Seeking Alpha)
Apr-12-25 05:30AM	Unpacking Global Fiscal And Trade Imbalances (Seeking Alpha)
03:00AM	March CPI Report: Risks Delayed, Not Removed (Seeking Alpha)
12:30AM	Fixed Income At The Crossroads Of Trade And Trust (Seeking Alpha)
Apr-11-25 08:45PM	The Launch, Lurch, Lift-Off Cycle (Seeking Alpha)
02:07PM	Does Bond Market Instability Result In The Fed Easing Sooner Than This Summer? (Seeking Alpha)
12:45PM	Cooler Inflation, Cloudy Outlook: What It Means For The Bond Market (Seeking Alpha)
08:10AM	The Consumer Is Tapping Out (Seeking Alpha)
06:30AM	Beneath The Skin Of CPI Inflation: Surging Prices Of Food, Housing, Medical Care Meet Plunging Prices Of Gasoline And Travel Services (Seeking Alpha)
04:30AM	Rates Spark: U.S. Yields Not For Turning, So Spreads Widen (Seeking Alpha)
04:00AM	Why A War On Trade Deficits Won't Reindustrialize America (Seeking Alpha)
03:15AM	Tariffs And The Economy (Seeking Alpha)
02:55AM	CPI And Weekly Jobless Claims (Seeking Alpha)
02:45AM	President Trump Blinks For Now, But Tariffs Remain High (Seeking Alpha)
Apr-10-25 11:15PM	Consumer Price Index: Inflation Cools To 2.4% In March (Seeking Alpha)
10:35PM	Optimism Burns Off On Reentry To Economic Doubt (Seeking Alpha)
02:00PM	AIER's Everyday Price Index Climbs Slightly In March 2025 (Seeking Alpha)
01:52PM	Consumer Prices Fall In March (Seeking Alpha)
10:45AM	A Pleasant Surprise From U.S. Inflation, But It Won't Last Long (Seeking Alpha)
07:30AM	3 Things - What Is Happening With Tariffs, Bonds And Risk Profiles? (Seeking Alpha)
04:30AM	Rates Spark: Demand For Safety To Stay (Seeking Alpha)
03:35AM	The U.S. Economy's Trajectory Amid Higher Tariffs (Seeking Alpha)
Apr-09-25 10:10AM	Fed Faces Difficult Balancing Act In A Global Trade War (Seeking Alpha)
09:05AM	The Fed Put Is Nowhere In Sight (Seeking Alpha)
08:23AM	Global Market Perspectives: The World Turned Upside Down (Seeking Alpha)
04:50AM	Rates Spark: Is Sell America Inc. Now A Thing? (Seeking Alpha)
03:30AM	The Tale Of Tariffs Round Two For The U.S. Economy (Seeking Alpha)
Apr-08-25 07:58AM	CIO Notebook: Payrolls To The Wings As Tariffs Take Center Stage (Seeking Alpha)
07:30AM	The Tariff Crash Of 2025: The Price Of Economic Amnesia (Seeking Alpha)
05:30AM	Trump, Powell And Rates: The Post-Liberation Day Edition (Seeking Alpha)

ProShares Short 20+ Year Treasury seeks daily investment results, before fees and expenses, that correspond to the inverse (-1x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index includes publicly-issued U.S. Treasury securities with minimum term to maturity greater than or equal to twenty years and have $300 million or more of outstanding face value, excluding amounts held by the Federal Reserve. The fund is non-diversified.

open in screener | open in yahoo | open in marketwatch | open in google

SCYX

Scynexis Inc

TBF

ProShares Short 20+ Year Treasury -1x Shares

Upgrade your FINVIZ experience